US5318895A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Aspergillus niger mutants
Assignee: Merck and Co Inc
•
Filing: 1992-10-05
•
Granted: 1994-06-07
•
Expires: 2012-10-05
Abstract
Abstract Disclosed are new Aspergillus niger mutants which can be used for identifying active FK-506/ rapamycin type, or cyclosporin A type inununosuppressants in a broth, natural product extract, or composition exhibiting inununosuppressant activity. Specifically disclosed are the new mutants, ATCC No. 74085 (MF 5659), which is sensitive to FK-506 and rapamycin but resistant to cyclosporin A; ATCC No. 74086 (MF 5659) which is resistant to FK-506, cyclosporin A and rapamycin; and ATCC No. 74087 (MF 5661) which is resistant to FK-506 and rapamycin, but sensitive to cyclosporin A.
Inventors
- 👤 Jennifer N. Kahn
- 👤 Kevin M. Byrne
- 👤 Louis Kaplan
- 👤 Richard J. Monaghan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 10:10
CPC Classifications
C; C12; C12N; C12N1/00; C12N1/14; C12N1/145; C12Q; C12Q1/00; C12Q1/02; C12Q1/025; C12R; C12R2001/00; C12R2001/645; C12R2001/66; C12R2001/685; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/911; Y10S435/913; Y10S435/917
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
14 words
A biologically pure form of an Aspergillus niger mutant identified as ATCC No. 74085.
Claim 2
Dependent Claim
14 words
A biologically pure form of an Aspergillus niger mutant identified as ATCC No. 74085.
Claim 3
Dependent Claim
14 words
A biologically pure form of an Aspergillus niger mutant identified as ATCC No. 74086.
Claim 4
Dependent Claim
14 words
A biologically pure form of an Aspergillus niger mutant identified as ATCC No. 74086.
Claim 5
Dependent Claim
14 words
A biologically pure form of an Aspergillus niger mutant identified as ATCC No. 74087.
Claim 6
Dependent Claim
14 words
A biologically pure form of an Aspergillus niger mutant identified as ATCC No. 74087.
Claim 7
Dependent Claim
78 words
A process for testing a compound or fermentation broth for cyclosporin immunosuppressant-type activity comprising the steps of: (1) contacting said compound or broth with: (a) Aspergillus niger ATCC No. 74085 mutant, and (b) AspergillUS niger ATCC No. 6275; (2) observing the conidiation characteristics of said ATCC No. 74085 mutant, which are positive in the presence of cyclosporin immunosuppressive-type activity, and (3) observing the conidiation characteristics of said ATCC No. 6275 which are negative in the presence of cyclosporin.
Claim 8
Dependent Claim
78 words
A process for testing a compound or fermentation broth for cyclosporin immunosuppressant-type activity comprising the steps of: (1) contacting said compound or broth with: (a) Aspergillus niger ATCC No. 74085 mutant, and (b) AspergillUS niger ATCC No. 6275; (2) observing the conidiation characteristics of said ATCC No. 74085 mutant, which are positive in the presence of cyclosporin immunosuppressive-type activity, and (3) observing the conidiation characteristics of said ATCC No. 6275 which are negative in the presence of cyclosporin.
Claim 9
Dependent Claim
83 words
A process for testing a compound or fermentation broth for FK-506/rapamycin immunosuppressant-type activity comprising the steps of: (1) contacting said compound or broth with (a) Aspergillus niger ATCC No. 74087 mutant and (b) Aspergillus niger ATCC No. 6275, and (2) observing the conidiation characteristics of said ATCC No. 74087 mutant, which are positive in the presence of FK-506/ rapamycin immunosuppressive-type activity, and (3) observing the conidiation characteristics of said ATCC No. 6275 which are negative in the presence of FK-506/rapamycin type immunosuppressant activity.
Claim 10
Dependent Claim
83 words
A process for testing a compound or fermentation broth for FK-506/rapamycin immunosuppressant-type activity comprising the steps of: (1) contacting said compound or broth with (a) Aspergillus niger ATCC No. 74087 mutant and (b) Aspergillus niger ATCC No. 6275, and (2) observing the conidiation characteristics of said ATCC No. 74087 mutant, which are positive in the presence of FK-506/ rapamycin immunosuppressive-type activity, and (3) observing the conidiation characteristics of said ATCC No. 6275 which are negative in the presence of FK-506/rapamycin type immunosuppressant activity.
Claim 11
Dependent Claim
124 words
A process for testing a compound or fermentation broth for FK-506/rapamycin type or cyclosporin A type immunosuppressant activity comprising the steps of: (1) contacting said compound or broth with (a) Aspergillus niger ATCC No. 74085 mutant (b) Aspergillus niger ATCC No. 74086 mutant; (c) Aspergillus niger ATCC No. 74087 mutant; (d) Aspergillus niger ATCC No. 6275; and (2) observing the conidiation characteristics of said mutants, which is: positive for ATCC No. 74086 and ATCC No. 74087, but negative for ATCC No. 74085 and ATCC No. 6275 in the presence of FK-506/rapamycin immunosuppressant-type activity; and positive for ATCC No. 74085 and ATCC No. 74086, but negative in the presence of ATCC No. 74087 and ATCC No. 6275 in the presence of cyclosporin A immunosuppressant-type activity.
Claim 12
Dependent Claim
124 words
A process for testing a compound or fermentation broth for FK-506/rapamycin type or cyclosporin A type immunosuppressant activity comprising the steps of: (1) contacting said compound or broth with (a) Aspergillus niger ATCC No. 74085 mutant (b) Aspergillus niger ATCC No. 74086 mutant; (c) Aspergillus niger ATCC No. 74087 mutant; (d) Aspergillus niger ATCC No. 6275; and (2) observing the conidiation characteristics of said mutants, which is: positive for ATCC No. 74086 and ATCC No. 74087, but negative for ATCC No. 74085 and ATCC No. 6275 in the presence of FK-506/rapamycin immunosuppressant-type activity; and positive for ATCC No. 74085 and ATCC No. 74086, but negative in the presence of ATCC No. 74087 and ATCC No. 6275 in the presence of cyclosporin A immunosuppressant-type activity.
References Cited (Backward Citations)
US3929992A
Cited
US4894366A
Cited
US5138052A
Cited
US5210030A
Cited
WO1992014737A1
Cited
US5093338A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-06-06 | 1997-12-06 | 1998-06-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-06-06 | 2001-12-06 | 2002-06-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-06-06 | 2005-12-06 | 2006-06-07 | $7700.00 | Window Closed / Lapsed |